Simpson Querrey Institute

SQI member Evangelos Kiskinis appeared on a recent Northwestern University Feinberg School of Medicine
Breakthroughs Podcast to discuss his work to uncover novel cellular mechanisms involved in two types of genetic ALS. The findings may lead to future targeted therapies.

Discovering New ALS Therapeutic Avenues with Evangelos Kiskinis, PhD An estimated 32,000 Americans are currently living with ALS, or amyotrophic lateral sclerosis, a progressive neurodegenerative disease that attacks motor neurons in the brain and spinal cord. Northwestern investigators have uncovered novel cellular mechanisms involved in two types of genetic ALS tha...

Jes Sanders is a fifth-year general surgery resident at Northwestern Memorial Hospital and a postdoctoral research fellow in the laboratory of SQI members James Mathew and Joseph Leventhal. In this interview, Sanders summarizes his main research project and explains why he was drawn to the field of transplant immunology.

Meet the Researchers: Jes Sanders: Simpson Querrey Institute (SQI) - Northwestern University In this interview, postdoctoral researcher Jes Sanders summarizes his Rising Stars of SQI Lecture and explains why he was drawn to the field of transplant immunology.

A research team led by SQI member Arun Sharma has developed a synthetic, flexible “bladder patch” that outperformed the current standard surgery for severe bladder dysfunction in a long-term, large-animal model — the last step before beginning clinical trials.

Synthetic ‘bladder patch’ promotes tissue regeneration, restores function: Simpson Querrey Institute (SQI) - Northwestern University A research team led by SQI member Arun Sharma has developed a synthetic, flexible “bladder patch” that outperformed the current standard surgery for severe bladder dysfunction in a long-term, large-animal model — the last step before beginning clinical trials.

Northwestern University researchers led by SQI member Evan Scott have developed the first selective therapy to prevent allergic reactions, which can range in severity from itchy hives and watery eyes to trouble breathing and even death.

Decorated nanoparticles prevent allergic reactions Northwestern University researchers have developed the first selective therapy to prevent allergic reactions, which can range in severity from itchy hives and watery eyes to trouble breathing and even death.